Cite
HARVARD Citation
Stahler, A. et al. (2021). Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial). European journal of cancer. pp. 71-80. [Online].